Autoantibodies against type 1 interferons linked to higher susceptibility to viral disease

FHS
July 18, 2024
11:16 pm

A new study shows that about two percent of the population develop autoantibodies against type 1 interferons, mostly later in life.

Judge’s ruling clears way for Aurion Biotech’s IPO, investor Alcon to appeal

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

January 30, 2025

Adjuvant Osimertinib as a Standard Therapy for EGFR-Positive NSCLC

Treatment with osimertinib (Tagrisso) after surgery significantly reduced the risk of death in adults with completely resected EGFR-positive stage IB, II, or IIIA non-small cell

July 7, 2023

Man takes 217 COVID vaccines with no ill effects, shows immune boost

A case report of a 62-year-old man receiving 217 SARS-CoV-2 vaccinations over 29 months reveals no adverse effects, increased T-cells, and spike-specific antibodies, providing unique

March 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.